Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H32O6S |
| Molecular Weight | 436.562 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COCC1=CC=CC(C[C@H](O)\C=C\[C@H]2[C@H](O)CC(=O)[C@@H]2CCSCCCC(O)=O)=C1
InChI
InChIKey=ORSJUPRAHPZYRL-XHTUOEPPSA-N
InChI=1S/C23H32O6S/c1-29-15-17-5-2-4-16(12-17)13-18(24)7-8-19-20(22(26)14-21(19)25)9-11-30-10-3-6-23(27)28/h2,4-5,7-8,12,18-21,24-25H,3,6,9-11,13-15H2,1H3,(H,27,28)/b8-7+/t18-,19-,20-,21-/m1/s1
Rivenprost (ONO-4819) is a potent and selective EP4 receptor agonist. This compound can increase bone formation by stimulating osteoblast differentiation and function, possibly by modulating mesenchymal cell differentiation. Rivenprost has also been studied for its potential to prevent bone loss (in osteoporosis) and stabilize bone implants. Combined with risedronate, rivenprost may be an effective treatment for osteoporosis. A phase II study evaluating rivenprost in ulcerative colitis was terminated in 2009.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
T7XW73LKW4
Created by
admin on Sat Dec 16 19:34:26 UTC 2023 , Edited by admin on Sat Dec 16 19:34:26 UTC 2023
|
PRIMARY | |||
|
256382-23-7
Created by
admin on Sat Dec 16 19:34:26 UTC 2023 , Edited by admin on Sat Dec 16 19:34:26 UTC 2023
|
PRIMARY | |||
|
DTXSID301102270
Created by
admin on Sat Dec 16 19:34:26 UTC 2023 , Edited by admin on Sat Dec 16 19:34:26 UTC 2023
|
PRIMARY | |||
|
9824353
Created by
admin on Sat Dec 16 19:34:26 UTC 2023 , Edited by admin on Sat Dec 16 19:34:26 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
